Thomas E Klema Net Worth

The estimated Net Worth of Thomas E Klema is at least 3.23 百万$ dollars as of 15 December 2017. Thomas Klema owns over 87,500 units of Rockwell Medical Inc stock worth over 3,106,435$ and over the last 21 years Thomas sold RMTI stock worth over 119,100$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Thomas Klema RMTI stock SEC Form 4 insiders trading

Thomas has made over 13 trades of the Rockwell Medical Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Thomas exercised 87,500 units of RMTI stock worth 568,750$ on 15 December 2017.

The largest trade Thomas's ever made was exercising 150,000 units of Rockwell Medical Inc stock on 18 June 2013 worth over 271,500$. On average, Thomas trades about 20,951 units every 122 days since 2003. As of 15 December 2017 Thomas still owns at least 757,667 units of Rockwell Medical Inc stock.

You can see the complete history of Thomas Klema stock trades at the bottom of the page.

What's Thomas Klema's mailing address?

Thomas's mailing address filed with the SEC is 30142 WIXOM ROAD, , WIXOM, MI, 48393.

Insiders trading at Rockwell Medical Inc

Over the last 21 years, insiders at Rockwell Medical Inc have traded over 3,082,721$ worth of Rockwell Medical Inc stock and bought 689,891 units worth 3,959,861$ . The most active insiders traders include Robert L Chioini、David S.Rbi Private Investm...、Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of 170,433$. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth 43,724$.

What does Rockwell Medical Inc do?

rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www

Complete history of Thomas Klema stock trades at Rockwell Medical Inc

Rockwell Medical Inc executives and stock owners

Rockwell Medical Inc executives and other stock owners filed with the SEC include:

• Raymond Pratt,
  Chief Development Officer
• Ajay Gupta,
  Chief Scientific Officer
• Dr. Russell H. Ellison M.Sc., M.D., MSc.,
  Pres, CEO & Director
• Dr. Raymond Dennis Pratt FACP, M.D.,
  Chief Devel. Officer
• Russell L. Skibsted M.B.A.,
  Exec. VP, CFO & Chief Bus. Officer
• John Cooper,
  Independent Director
• Mark Ravich,
  Independent Director
• John McLaughlin,
  Independent Chairman of the Board
• Robert Radie,
  Independent Director
• Marc Hoffman,
  Chief Medical Officer
• Michael DeYoung,
  Vice President - Operations
• Paul McGarry,
  Principal Accounting Officer, Vice President, Corporate Controller
• Jim McCarthy,
  Senior Vice President - Corporate and Business Development
• Russell Skibsted,
  Executive Vice President, Chief Financial Officer and Chief Business Officer
• Russell Ellison,
  President, Chief Executive Officer, Director
• David J. Kull,
  Sec.
• Dr. Marc L. Hoffman,
  Chief Medical Officer
• Timothy T. Chole,
  Sr. VP of Sales & Marketing
• Megan C. Timmins,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Paul E. McGarry,
  VP, Corp. Controller & Principal Accounting Officer
• Tim Chole,
  VP of Marketing
• Anne Boardman,
  VP of Sales and Strategic Accounts
• James A. McCarthy,
  Sr. VP of Bus. & Corp. Devel.
• Michael Costello,
  Gen. Counsel
• David S.Rbi Private Investm...,
  
• Patrick J Bagley,
  Director
• Ronald D Boyd,
  Director
• Robin L Smith,
  Director
• Kenneth L Holt,
  Director
• Allen Nissenson,
  Director
• Stuart M Paul,
  Chief Executive Officer
• Brothers, Inc.Richmond Davi...,
  
• Benjamin Wolin,
  Director
• Lisa N Colleran,
  Director
• Mark H Ravich,
  Director
• David Kull,
  Principal Accounting Officer
• David S.Rbi Private Investm...,
  
• Angus W. Smith,
  Chief Financial Officer
• David S.Rbi Private Investm...,
  
• Mark Strobeck,
  President and CEO
• David A Hagelstein,
  10% owner
• Annamaria T Kausz,
  VP of Drug Development
• Robert L Chioini,
  Chairman, President and CEO
• Richard C Yocum,
  VP - Clin. Dev. & Med. Affairs
• Thomas E Klema,
  Vice President, CFO
• Megan C. Timmins,
  EVP, CLO and Secretary
• David S.Rbi Private Investm...,
  
• Joan Lau,
  Director
• Jesse Neri,
  SVP, FINANCE